Navigation Links
July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia

s have been reported infrequently. As with other fluoroquinolones, FACTIVE should be used with caution in patients with known or suspected CNS diseases. If CNS reactions occur, FACTIVE should be discontinued and appropriate measures instituted.

No significant drug-drug interactions were seen with theophylline, digoxin, oral contraceptives, cimetidine, omeprazole, and warfarin, although patients receiving a fluoroquinolone concomitantly with warfarin should be monitored closely. Drug-drug interactions include probenicid, sucralfate, antacids containing aluminum or magnesium, iron, multivitamins containing metal cations, and didanosine. The safety and effectiveness of FACTIVE in children, adolescents (less than 18 years of age), pregnant women, and lactating women have not been established. For complete safety and efficacy information, please see the full prescribing information available at www.factive.com.

Forward-Looking Statement

This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to the importance of a short course of therapy for the treatment of CAP. Forward-looking statements represent our management's judgment regarding future events. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "intend," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. We do not plan to update these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of risks affecting our business. These risks include, but are not limited to (a) our ability to successfully commercialize and market ANTARA or FACTIVE due to: the limitations on our resources and experience in the commercialization of products
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. FDA Issues Safety Alert on Avandia
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
7. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/16/2008)...de industry and customer thought leaders -, SAN F...recognized,leader and trusted resource for clinica...tellation of prestigious academic medical centers,...s annual user group meeting in San,Francisco. The ...lly and,collaboratively manage thousands of clinic...
(Date:5/16/2008)...al Biomarkers -- for Lung Cancer Diagnosis and, Id...er of Unknown Primary ... Types With High Sensitivity and, Specificity an...ancer Results of microRNA Signature to Identify T...eding 90% and Specificity of 99%, REHOVOT, Israel...
(Date:5/15/2008)... May 15 /- Eisai Corporation of North...ical data abstracts about,compounds in the company...nical oncology research have been accepted for pre...an Society of Clinical Oncology (ASCO),taking pla...e variety of abstracts on Eisai marketed products ...
(Date:5/15/2008)... at ASCO Showed Acceptable Tolerability Profile, ...ropathy, WOODCLIFF LAKE, N.J., May 15 /PRNewswire...ibulin mesylate (E7389) demonstrated activity in a...ly advanced or metastatic,breast cancer, according...ial. The study also suggests that eribulin mesylat...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Prize for Cutting Edge Laser Innovations 2193 1Prize for Cutting Edge Laser Innovations 2193 2Governor Rendell Appoints Dr Richard Snyder of Independence Blue Cross to Chronic Care Commission 2188 1Governor Rendell Appoints Dr Richard Snyder of Independence Blue Cross to Chronic Care Commission 2188 2Governor Rendell Appoints Dr Richard Snyder of Independence Blue Cross to Chronic Care Commission 2188 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX 28R 29 28clopidogrel bisulfate 29 892 1FDA Approves New 300mg Loading Dose Tablet for PLAVIX 28R 29 28clopidogrel bisulfate 29 892 2FDA Approves New 300mg Loading Dose Tablet for PLAVIX 28R 29 28clopidogrel bisulfate 29 892 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX 28R 29 28clopidogrel bisulfate 29 892 4FDA Approves New 300mg Loading Dose Tablet for PLAVIX 28R 29 28clopidogrel bisulfate 29 892 5London School of Hygiene to play key role in global collaboration on adverse drug reactions 2185 1London School of Hygiene to play key role in global collaboration on adverse drug reactions 2185 2
...)--Jun 18, 2007 - Salix,Pharmaceuticals, Ltd. (NAS...n and outcome of its Phase III registration trial ...mg tablet,formulation of balsalazide disodium (bal...ive ingredient in COLAZAL(R),Capsules 750 mg, an a...e treatment of mildly to moderately active ulcerat...
...)--Jun 18, 2007 - Novelos,Therapeutics, Inc. (OTCB...he development of therapeutics to treat cancer and... an ongoing,Dana-Farber/Partners Cancer Care (DF/P...arboplatin in platinum-resistant ovarian,cancer pa...st,overall tumor response (assessed at least after...
Other Medicine Technology:Salix Pharmaceuticals Announces Positive Top Line Results of,Balsalazide Tablets Registration Study 2Salix Pharmaceuticals Announces Positive Top Line Results of,Balsalazide Tablets Registration Study 3Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 2Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 3
(Date:5/16/2008)...SBURG, Pa., May 16 /PRNewswire-USNewswire/ -- Emer...portunity to highlight the dedication,of Pennsylva... to become,trained EMS volunteers, according to st... year,s theme, "EMS: Your Life is Our Mission," em...hen it occurs, EMS is there to provide,immediate, ...
(Date:5/16/2008)...eals for Funds Focus on Millions of Children Still...U.S. Fund for UNICEF and The,Advertising Council t...mote,a series of national public service announcem...g Ben Stiller, Nicole Ritchie, Joel Madden, David,...o help survivors of the,Myanmar cyclone. The Ad Co...
(Date:5/16/2008)...IEGO, May 16 /PRNewswire-FirstCall/ -- CryoCor, In...d on the treatment of cardiac,arrhythmias, announc...of,CryoCor common stock filed a complaint in the S...f San Diego, naming as defendants each member of t...on Scientific Corporation.,The complaint is styled...
(Date:5/16/2008)...tch in some early stage cases makes therapy of lit...Y, May 16 (HealthDay News) -- Colon cancer patient... to receive chemotherapy. In fact, not only does c... may actually harm them, a new study found. , "I...], then you should not be treated with chemotherap...
Breaking Medicine News(10 mins):Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...n his family’s farm near Stowmarket Suffolk, has c...h by rabbit flu.// John Freeman, 29, had become i...ter he had picked up a rabbit on his farm. His mot...l the following day and succumbed to the infection...
...ices at supermarkets has taken root. These clinics...o simply hate waiting. These clinics// can provide...infections and sprains. Take Care Health Systems ...at Walgreens drugstores in Chicago. But Dr. Peter ...
... travelling on a My Travel flight to Newcastle las...by son in Tenerife after the captain// of the plan...spot on his head. The captain thought it was chick...ndparents since his mom had an interview to attend...
...hting tooth decay has been developed by BASF, a Ge...s next year. The company claims its// product can...h by 50 times. The product was developed in colla...rganoBalance. The gum helps in fighting tooth de...
Other Medicine News:
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: